# Kissei Pharmaceutical Co., Ltd. clinical trials: 63 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 63 trials with Kissei Pharmaceutical Co., Ltd. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Kissei Pharmaceutical Co., Ltd.: 63 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/kissei-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 63
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 25 newest of 63, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 22, 2026 | NCT07604064 | A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia | Kissei Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Relapsed or Refractory IDH1 Mutation-Positive Acute Myeloid Leukemia | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604064) |
| June 27, 2025 | NCT07040137 | Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Spinocerebellar Degeneration | 142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07040137) |
| June 11, 2025 | NCT07015268 | A Clinical Study of KLH-2109 in Patients With Endometriosis | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Active not recruiting | Endometriosis | 288 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07015268) |
| January 3, 2025 | NCT06758271 | Special Drug Use-results Survey for Long-term Use（Avacopan） | Kissei Pharmaceutical Co., Ltd. | Observational | Recruiting | Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA) | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06758271) |
| January 3, 2025 | NCT06757257 | Special Drug Use-results Survey for Long-term Use (Fostamatinib) | Kissei Pharmaceutical Co., Ltd. | Observational | Recruiting | Chronic Idiopathic Thrombocytopenic Purpura | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06757257) |
| December 9, 2024 | NCT06722729 | A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease | Kissei Pharmaceutical Co., Ltd. | Phase 2 | Completed | Parkinson Disease | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06722729) |
| April 26, 2023 | NCT05831670 | An Early Phase 2 Clinical Study of KSP-0243 | Kissei Pharmaceutical Co., Ltd. | Phase 2 | Completed | Colitis, Ulcerative | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05831670) |
| July 6, 2022 | NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Uterine Fibroids (MeSH Heading: Leiomyoma) | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05445167) |
| June 30, 2022 | NCT05440383 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Uterine Fibroids (MeSH Heading: Leiomyoma) | 287 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05440383) |
| April 30, 2021 | NCT04867551 | A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease | Kissei Pharmaceutical Co., Ltd. | Phase 2 | Completed | Parkinson Disease | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04867551) |
| January 15, 2021 | NCT04711603 | A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Uremic Pruritus | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04711603) |
| May 1, 2020 | NCT04372121 | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Terminated | Endometriosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04372121) |
| April 6, 2020 | NCT04335591 | Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6) | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Endometriosis | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04335591) |
| October 18, 2019 | NCT04132050 | A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Idiopathic Thrombocytopenic Purpura | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04132050) |
| June 20, 2019 | NCT03992846 | Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain. | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Endometriosis | 486 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03992846) |
| June 14, 2019 | NCT03986944 | A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Terminated | Endometriosis | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03986944) |
| February 19, 2019 | NCT03845387 | A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease. | Kissei Pharmaceutical Co., Ltd. | Phase 2 | Completed | Parkinson Disease | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03845387) |
| January 14, 2019 | NCT03802617 | A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. | Kissei Pharmaceutical Co., Ltd. | Phase 2 | Completed | Uremic Pruritus | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03802617) |
| June 6, 2017 | NCT03177668 | Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma | Kissei Pharmaceutical Co., Ltd. | Phase 1/2 | Completed | Malignant Pleural Mesothelioma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03177668) |
| March 1, 2017 | NCT03068481 | Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease | Kissei Pharmaceutical Co., Ltd. | Phase 1 | Completed | Parkinson Disease | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03068481) |
| September 23, 2016 | NCT02912533 | A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Anemia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02912533) |
| September 23, 2016 | NCT02912494 | A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Anemia | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02912494) |
| September 5, 2016 | NCT02889302 | An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Spinocerebellar Degeneration | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02889302) |
| May 20, 2016 | NCT02778919 | Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis | Kissei Pharmaceutical Co., Ltd. | Phase 2 | Completed | Endometriosis | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02778919) |
| July 20, 2015 | NCT02503189 | A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome | Kissei Pharmaceutical Co., Ltd. | Phase 3 | Completed | Dry Eye With Sjögren's Syndrome | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02503189) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 28 |
| Phase 3 | 28 |
| Phase 4 | 1 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 54 |
| Terminated | 3 |
| Recruiting | 3 |
| Active not recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Endometriosis | 9 |
| Spinocerebellar Degenerations | 9 |
| Dry Eye Syndromes | 8 |
| Corneal Diseases | 8 |
| Conjunctival Diseases | 8 |
| Constipation | 7 |
| Hyperphosphatemia | 5 |
| Parkinson Disease | 4 |
| Spinocerebellar Ataxias | 4 |
| Dysmenorrhea | 4 |
| Dyspareunia | 4 |
| Urinary Bladder, Overactive | 3 |
| Urinary Incontinence, Urge | 3 |
| Gastrointestinal Diseases | 3 |
| Leiomyoma | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Anemia | 2 |
| Diabetes Mellitus | 1 |
| Fasting | 1 |
| Insulin Resistance | 1 |
| Hyperuricemia | 1 |
| Purpura, Thrombocytopenic, Idiopathic | 1 |
| Recurrence | 1 |
| Colitis, Ulcerative | 1 |
| Prostatic Hyperplasia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Animation studios in the United States](https://specstream.ai/data/businesses/animation-studios/united-states)
- [Art restoration companies in the United States](https://specstream.ai/data/businesses/art-restoration-companies/united-states)
- [AV equipment rental companies in the United States](https://specstream.ai/data/businesses/av-equipment-rental-companies/united-states)
- [B2B equipment maintenance and repair companies in the United States](https://specstream.ai/data/businesses/b2b-equipment-maintenance-and-repair-companies/united-states)
- [B2B oil refinery companies in the United States](https://specstream.ai/data/businesses/b2b-oil-refinery-companies/united-states)
